ABOS
Acumen Pharmaceuticals, Inc.2.1000
+0.0400+1.94%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
127.20MP/E (TTM)
-Basic EPS (TTM)
-2.21Dividend Yield
0%Recent Filings
8-K
Acumen raises $35.75M privately
Acumen Pharmaceuticals signed a securities purchase agreement on March 13, 2026, to sell 10,833,331 common shares at $3.30 each to institutional investors, expecting ~$35.75M gross proceeds before fees. Closing set for March 16, subject to conditions; funds target Enhanced Brain Delivery program preclinical work for a lead candidate and general purposes. Yet closing risks loom if conditions fail.
8-K
Updated deck adds EBD data
Acumen updated its corporate deck on January 12, 2026, adding nonclinical murine brain exposure data for the EBD program from CTAD 2025, refreshed Phase 1 INTERCEPT-AD fluid biomarkers, and slotted ACU234 into the pipeline. Phase 2 ALTITUDE-AD topline hits late 2026; EBD candidate data early 2026. Cash lasts into early 2027. Pipeline advances swiftly.
8-K
Q3 cash $136M, R&D down
Acumen Pharmaceuticals reported Q3 2025 results, with cash at $136.1 million funding operations into early 2027 while R&D expenses dropped to $22.0 million from $27.2 million year-over-year. Phase 2 ALTITUDE-AD enrollment complete; topline data due late 2026. Board adds Chairman George Golumbeski. Cash burn slowed sharply.
10-Q
Q3 FY2025 results
Acumen trimmed Q3 operating expenses 18% y/y to $26.5M, narrowing net loss to $26.5M ($0.44/share) from $29.8M ($0.50/share), driven by 19% lower R&D at $22.0M after completing ALTITUDE-AD enrollment. YTD net loss widened to $96.2M from $65.2M on 42% higher R&D spend for manufacturing and trials, offset by $2.4M other income. Cash plus marketable securities stood at $136.1M against $30.7M debt (14.0% effective rate, matures 2027), funding ops into early 2027; operating cash burn hit $96.4M. Signed JCR collab in July 2025 for EBD therapy, paying upfront (expensed). Cash burn accelerates.
8-K
Golumbeski named Chairman
Acumen Pharmaceuticals appointed Dr. George Golumbeski, pharma veteran from Celgene and Novartis, as independent Class II director and Chairman, effective November 6, 2025, replacing Dr. Sean Stalfort. He received a stock option for 50,000 shares and $70,000 annual retainers. Board hits eight members. His deal-making expertise bolsters strategy amid Phase 2 Alzheimer's catalysts.
ABVC
ABVC Biopharma, Inc.
2.06-0.01
ACET
Adicet Bio, Inc.
0.47-0.03
ACIU
AC Immune SA
3.29+0.05
ACOG
Alpha Cognition Inc.
5.43+0.42
ALEC
Alector, Inc.
1.39-0.03
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANVS
Annovis Bio, Inc.
3.93+0.15
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
IGC
IGC Pharma, Inc.
0.34+0.00
SABS
SAB Biotherapeutics, Inc.
3.99-0.01